• Something wrong with this record ?

Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer

KM. Gust, K. Rebhan, I. Resch, SF. Shariat, A. Necchi,

. 2020 ; 30 (4) : 547-556. [pub] -

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc20028040

PURPOSE OF REVIEW: Immune-checkpoint inhibitors (CPIs) have been implemented in the treatment algorithm of metastatic urothelial cancer as they have shown higher and more sustained responses compared with conventional second-line chemotherapy. Recently, several clinical trials have reported on CPIs in earlier disease stages such as muscle-invasive bladder cancer (MIBC). This review summarizes ongoing clinical trials and results from early phase clinical trials in muscle invasive and locally advanced bladder cancer. RECENT FINDINGS: In phase II clinical trials, neoadjuvant use of CPIs as mono and combination therapy, in patients with MIBC planned for radical cystectomy, has shown promising pathological complete response rates. Whether this will translate in survival benefit remains to be assessed. Combination of CPIs and conventional chemotherapy or other targeted agents promises to increase the efficacy of perioperative systemic therapy with potentially additive toxicities. Recently, preclinical models of combined trimodal therapy with CPIs delivered the proof of principle leading to several ongoing trials in this setting. SUMMARY: First results of clinical trials evaluating CPIs in MIBC demonstrate very promising results that warrant further investigation as they could revolutionize management of MIBC in the near future. The trend and hope are toward higher rates of safe and sustained bladder preservation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028040
003      
CZ-PrNML
005      
20210114152844.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000000783 $2 doi
035    __
$a (PubMed)32453001
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gust, Kilian M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna. Karl Landsteiner Institute, Vienna, Austria.
245    10
$a Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer / $c KM. Gust, K. Rebhan, I. Resch, SF. Shariat, A. Necchi,
520    9_
$a PURPOSE OF REVIEW: Immune-checkpoint inhibitors (CPIs) have been implemented in the treatment algorithm of metastatic urothelial cancer as they have shown higher and more sustained responses compared with conventional second-line chemotherapy. Recently, several clinical trials have reported on CPIs in earlier disease stages such as muscle-invasive bladder cancer (MIBC). This review summarizes ongoing clinical trials and results from early phase clinical trials in muscle invasive and locally advanced bladder cancer. RECENT FINDINGS: In phase II clinical trials, neoadjuvant use of CPIs as mono and combination therapy, in patients with MIBC planned for radical cystectomy, has shown promising pathological complete response rates. Whether this will translate in survival benefit remains to be assessed. Combination of CPIs and conventional chemotherapy or other targeted agents promises to increase the efficacy of perioperative systemic therapy with potentially additive toxicities. Recently, preclinical models of combined trimodal therapy with CPIs delivered the proof of principle leading to several ongoing trials in this setting. SUMMARY: First results of clinical trials evaluating CPIs in MIBC demonstrate very promising results that warrant further investigation as they could revolutionize management of MIBC in the near future. The trend and hope are toward higher rates of safe and sustained bladder preservation.
650    _2
$a karcinom z přechodných buněk $x farmakoterapie $x patologie $7 D002295
650    12
$a klinické zkoušky, fáze II jako téma $7 D017322
650    _2
$a cystektomie $7 D015653
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    _2
$a nádory svalů $x farmakoterapie $x patologie $7 D019042
650    _2
$a neoadjuvantní terapie $x metody $7 D020360
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Rebhan, Katharina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna.
700    1_
$a Resch, Irene $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna.
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna. Karl Landsteiner Institute, Vienna, Austria. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. Department of Urology, Weill Cornell Medical College, New York, New York, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, University of Jordan, Amman, Jordan.
700    1_
$a Necchi, Andrea $u Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 4 (2020), s. 547-556
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32453001 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152841 $b ABA008
999    __
$a ok $b bmc $g 1608375 $s 1119220
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 30 $c 4 $d 547-556 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options